Cancer Forums and News by PhD's

News | Forums Register

Go Back   Cancer Forums and News by PhD's > Cancer Forums and News

Cancer News


Cancer Review


Recent Forum Topics

Double Binding Sites on Tumors Could Provide Future Combo Therapy
By Dross at 2008-04-09 00:56

Researchers from the University of Pennsylvania School of Medicine and colleagues at Merck Serono Research in Germany have found that two drugs bind to receptor sites on some tumors in different places at the same time, suggesting the possibility of a new combination therapy for certain types of cancer.

An increasing number of therapies targeting tumors that have proteins called epidermal growth factor receptors (EGFRtermtermterm) sitting on their surface are already being used in the clinic or are in late stages of development. For example, Herceptin is an established treatment for certain types of breast cancer and Erbituxterm and Vectibixterm are in use for other types of cancer. An additional drug called matuzumab is in phase II clinical trials.

read more | 1554 reads

Amgen discontinue Vectibix trial
By Dross at 2007-03-27 02:44

Amgen (NASDAQ: AMGN) announced that it has discontinued Vectibixterm(TM) (panitumumabtermterm) treatment in the PACCE trial evaluating the addition of Vectibix to standard chemotherapyterm and Avastinterm(R)(bevacizumabtermterm) for the treatment of first-line metastaticterm colorectal cancer (mCRC). The PACCE trial investigated a treatment regimen that used dual biologics combined with oxaliplatintermterm- or irinotecantermterm-based chemotherapy. This regimen is not currently used in clinical practice.


The decision to discontinue Vectibix treatment in the trial was based on a preliminary review of data from a pre-planned interim efficacy analysis scheduled after the first 231 events (death or disease progression). This analysis revealed a statistically significant difference in progression-free survival in favor of the control arm. An unplanned analysis of overall survival also demonstrated a statistically significant difference favoring the control arm. Additional analyses are ongoing, and Amgen plans to present the results at an upcoming scientific forum.

1738 reads

Colorectal Cancer Basics
By HCat at 2007-01-16 12:35

Colorectal Cancer Basics


Hereditary CRC

Colorectal cancer (CRC) can be divided into two basic types, hereditary or sporadic.

    Hereditary CRC are germlineterm (passed to offspring) mutations (a damaging change in DNA) with two well described forms. These hereditary mutations are thought to reduce the time it takes for the cells to turn cancerous. Mutations can be thought of in terms of “hits”. One hit is one mutation. It is thought that a normal cell needs 3 to 6 hits to become cancerous. With an inherited mutation, there is one fewer hit needed to reach the correct number to transform the cell to cancer. One odd aspect to CRC is that there is a relatively well defined set of events for the progression from adenomaterm to carcinomaterm.

read more | 29295 reads

Antibody vs Antibody
By Dross at 2007-01-13 04:31

Panitumumabtermterm, otherwise known as Vectibixterm, is the first fully human monoclonal antibodyterm directed against the EGFRtermtermterm receptor which is expressed on the surface of 75% of colorectal cancers. It was also approved by the fda this month, so knowledge of its efficacy could help you in discussing options in the treatment of your cancer. Be sure to ask your doctor about this human antibody and be sure to use the name of the drug when discussing it rather than the term "antibody" as there are many antibodies currently being used or approved for the treatment of cancer. What is the difference between Erbituxterm and Vectibix? Vectibix, (the fully human derived antibody) showed a 3% lesser amount of rash type immunolgical reactions than Erbitux.

read more | 4681 reads

Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in m
By Dross at 2007-01-04 07:32

While Vectibixterm (Amgen) alone only shows an 8% partial response rate, it shows a 46% reduction in tumor progression. Using the agent in combination with irinotecantermterm is therefore a novel and interesting approach which many centers are now exploring. If you center is not using this, or Erbituxterm (another monoclonal antibodyterm, ImClone, 10% response rate), then you should be asking why?


[via Entrez PubMed]:

read more | 1915 reads

FDA Approves a New Drug for Colorectal Cancer, Vectibix
By admin at 2006-11-22 10:47

The Food and Drug Administration (FDA) today approved Vectibixterm (panitumumabtermterm) for the treatment of patients with colorectal cancer that has metastasized (spread to other parts of the body) following standard chemotherapyterm. Vectibix, a monoclonal antibodyterm that binds to a protein called epidermal growth factor receptor or EGFRtermtermterm on some cancer cells, received an accelerated approval after showing effectiveness in slowing tumor growth and, in some cases, reducing the size of the tumor. In the United States, it is estimated that 150,000 new cases of colon cancer will be diagnosed and 55,000 deaths will occur from colon and rectal cancer in 2006. Approximately 70 percent of all colorectal carcinomas test positive for EGFR.

read more | 2236 reads

Syndicate content

sponsored links



Subscribe to our newsletter to receive info on our site or upcoming clinical trials

Confirm your email address

HTML format

Please select the newsletters you want to sign up to:

  • Cancerfocus
    Receive updates from Cancerfocus.
  • Breast
  • Colon
  • Kidney
  • Leukemia
  • Liver
  • Lung
  • Melanoma
  • Mesothelioma
  • Myeloma
  • Neck
  • Pancreatic
  • Prostate

Syndicate content

All times are GMT -5. The time now is 02:32 AM.